Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution

T. J. Gillespie, A. Erenberg, S. Kim, J. Dong, J. E. Taylor, V. Hau, Thomas P Davis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The biodistribution of several radiolabeled somatostatin (SRIF) analogs was determined in the rat. Newly developed analogs BIM-23190 and BIM-23197 attained higher plasma levels and much greater target tissue concentrations than the clinically used BIM-23014 analog. Highest tissue concentrations of BIM-23190 and BIM-23197 were found in adrenal, kidney, pituitary and pancreas, tissues that are known to be abundant in mRNA for the somatostatin subtype 2 receptor. BIM-23190 and BIM-23197 associated radioactivity in these tissues was prolonged compared with that of BIM-23014, especially in the SRIF-receptor-rich pituitary. BIM-23190 and BIM-23197 were more stable in vivo and much less subject to biliary excretion than BIM-23014. These properties account for the elevated plasma and target tissue concentrations of these new SRIF analogs. Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer.

Original languageEnglish (US)
Pages (from-to)95-104
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume285
Issue number1
StatePublished - Apr 1998

Fingerprint

Acromegaly
Somatostatin
Neoplasms
Radioactivity
Pancreas
BIM 23190
BIM 23197
Kidney
Messenger RNA
lanreotide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. / Gillespie, T. J.; Erenberg, A.; Kim, S.; Dong, J.; Taylor, J. E.; Hau, V.; Davis, Thomas P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 285, No. 1, 04.1998, p. 95-104.

Research output: Contribution to journalArticle

@article{a5fc4526cc4e441695fd85f830a0bd02,
title = "Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution",
abstract = "The biodistribution of several radiolabeled somatostatin (SRIF) analogs was determined in the rat. Newly developed analogs BIM-23190 and BIM-23197 attained higher plasma levels and much greater target tissue concentrations than the clinically used BIM-23014 analog. Highest tissue concentrations of BIM-23190 and BIM-23197 were found in adrenal, kidney, pituitary and pancreas, tissues that are known to be abundant in mRNA for the somatostatin subtype 2 receptor. BIM-23190 and BIM-23197 associated radioactivity in these tissues was prolonged compared with that of BIM-23014, especially in the SRIF-receptor-rich pituitary. BIM-23190 and BIM-23197 were more stable in vivo and much less subject to biliary excretion than BIM-23014. These properties account for the elevated plasma and target tissue concentrations of these new SRIF analogs. Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer.",
author = "Gillespie, {T. J.} and A. Erenberg and S. Kim and J. Dong and Taylor, {J. E.} and V. Hau and Davis, {Thomas P}",
year = "1998",
month = "4",
language = "English (US)",
volume = "285",
pages = "95--104",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution

AU - Gillespie, T. J.

AU - Erenberg, A.

AU - Kim, S.

AU - Dong, J.

AU - Taylor, J. E.

AU - Hau, V.

AU - Davis, Thomas P

PY - 1998/4

Y1 - 1998/4

N2 - The biodistribution of several radiolabeled somatostatin (SRIF) analogs was determined in the rat. Newly developed analogs BIM-23190 and BIM-23197 attained higher plasma levels and much greater target tissue concentrations than the clinically used BIM-23014 analog. Highest tissue concentrations of BIM-23190 and BIM-23197 were found in adrenal, kidney, pituitary and pancreas, tissues that are known to be abundant in mRNA for the somatostatin subtype 2 receptor. BIM-23190 and BIM-23197 associated radioactivity in these tissues was prolonged compared with that of BIM-23014, especially in the SRIF-receptor-rich pituitary. BIM-23190 and BIM-23197 were more stable in vivo and much less subject to biliary excretion than BIM-23014. These properties account for the elevated plasma and target tissue concentrations of these new SRIF analogs. Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer.

AB - The biodistribution of several radiolabeled somatostatin (SRIF) analogs was determined in the rat. Newly developed analogs BIM-23190 and BIM-23197 attained higher plasma levels and much greater target tissue concentrations than the clinically used BIM-23014 analog. Highest tissue concentrations of BIM-23190 and BIM-23197 were found in adrenal, kidney, pituitary and pancreas, tissues that are known to be abundant in mRNA for the somatostatin subtype 2 receptor. BIM-23190 and BIM-23197 associated radioactivity in these tissues was prolonged compared with that of BIM-23014, especially in the SRIF-receptor-rich pituitary. BIM-23190 and BIM-23197 were more stable in vivo and much less subject to biliary excretion than BIM-23014. These properties account for the elevated plasma and target tissue concentrations of these new SRIF analogs. Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031980378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031980378&partnerID=8YFLogxK

M3 - Article

VL - 285

SP - 95

EP - 104

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -